Neuroblastoma Treatment Options

• Treatment for your child’s neuroblastoma is individualized, guided mainly by age at diagnosis, tumor stage, and biological features such as MYCN gene status.
• Options range from careful observation for some low-risk tumors to a multidisciplinary combination of surgery, chemotherapy, radiation, and immunotherapy for high-risk disease.
• Newer approaches under study, including ALK inhibitors for tumors with ALK gene changes, remain investigational within clinical trials, mainly for high-risk or relapsed cases.
• Managing side effects during therapy and arranging long-term follow-up care afterward are both essential parts of your child’s treatment plan.
• Clinical trials play a vital role in accessing newer therapies and shaping future treatment protocols for children with neuroblastoma.

Understanding Neuroblastoma Treatment

Neuroblastoma treatment is planned individually for each child, based on a careful review of the tumor’s biology and your child’s overall health. Because the disease behaves very differently from one child to the next, no single protocol fits every case.

Factors Guiding Treatment Decisions

Several factors guide the choice of neuroblastoma treatment for your child, including your child’s age at diagnosis, where the tumor started, how far it has spread, and biological features of the tumor cells — especially whether the MYCN gene is amplified and whether the ALK gene is altered. According to the National Cancer Institute, these factors, together with tumor histology and how much of the tumor can be removed by surgery, are combined into a risk-group classification that guides therapy. A multidisciplinary team — typically a pediatric oncologist, surgeon, radiation oncologist, and pathologist — reviews these factors together to build a plan suited to your child.

Staging and Risk Stratification

International Neuroblastoma Risk Group Staging System criteria are used to stage neuroblastoma before treatment begins — you may see this referred to as INRGSS in your child’s chart. This presurgical, imaging-based approach is now standard in most North American and European treatment centers. Older records may instead cite the International Neuroblastoma Staging System (INSS), a surgery-based approach used before INRGSS became widespread. Staging results, combined with age and tumor biology, place the cancer into one of three risk groups: low, intermediate, or high. Children with low-risk or intermediate-risk disease usually respond well and can often be cured, whereas high-risk neuroblastoma is tougher to treat and needs more intensive therapy — this risk group, more than the stage alone, shapes how your child’s treatment plan is built.

Key Neuroblastoma Treatment Modalities

The core types of neuroblastoma therapy are combined differently depending on risk group, and several are often used together rather than on their own.

Surgical Intervention and Chemotherapy

The surgeon removes as much tumor tissue as it is safe to take out, and nearby lymph nodes are checked at the same time for signs of disease. Not every child needs surgery right away: for some low-risk tumors, particularly small adrenal tumors found in babies under six months old who have no symptoms, doctors may recommend observation instead, since these tumors can shrink or disappear without any treatment. When surgery alone is not enough, chemotherapy is added — given before surgery to shrink a large tumor, or afterward to clear any cancer cells left behind. For high-risk neuroblastoma, high-dose chemotherapy followed by a reinfusion of your child’s own stored (autologous) stem cells is a standard part of consolidation treatment, allowing doctors to use more intensive chemotherapy safely.

Radiation and Immunotherapy

Radiation treatment aims high-energy beams at the tumor site to kill cancer cells or slow their growth; it is used mainly for high-risk neuroblastoma or when a tumor keeps growing despite chemotherapy. A specialized form, iodine-131 MIBG therapy, uses a radioactive iodine compound that neuroblastoma cells take up, carrying radiation straight to the tumor; it may be used when high-risk neuroblastoma relapses after first-line treatment. Immunotherapy is a key part of maintenance treatment for high-risk disease: dinutuximab, an anti-GD2 monoclonal antibody, is FDA-approved for children with high-risk neuroblastoma who responded at least partially to initial chemotherapy, surgery, and stem cell transplant, and is given together with GM-CSF, interleukin-2, and isotretinoin to help the immune system target any remaining cancer cells.

Tailoring Neuroblastoma Treatment for Children

Because neuroblastoma is overwhelmingly a disease of infancy and early childhood, treatment plans are built around a growing body, not adapted from adult cancer protocols.

Age and Risk-Adapted Protocols

Your child’s age and risk group together shape the treatment plan. Babies under six months of age with small, localized adrenal tumors and no symptoms are often candidates for observation alone, since some of these tumors regress spontaneously and disappear without surgery or chemotherapy. Older children, and any child with high-risk disease, typically need a multi-modal approach: induction chemotherapy and surgery, followed by high-dose chemotherapy with stem cell rescue, then radiation and immunotherapy during maintenance. These protocols are continually refined through clinical trials that aim to preserve strong outcomes while limiting toxicity in growing children.

Addressing Unique Pediatric Needs

Treating a child with neuroblastoma involves more than eliminating the tumor. Pediatric oncologists also weigh how treatment may affect organ function, growth, fertility, and cognitive development over time. Supportive care — nutritional support, psychological counseling, and rehabilitation services — is built into the plan from the start, so your child’s care team is thinking about life after treatment even while therapy is underway.

Managing Side Effects and Long-Term Outcomes

Because neuroblastoma treatment is intensive, especially for high-risk disease, managing side effects and planning for the years after treatment are both central to your child’s care.

Strategies for Side Effect Management

Intensive treatment can cause nausea, fatigue, hair loss, a higher risk of infection from low blood cell counts, and strain on organ function. Care teams manage these proactively with antiemetics for nausea, growth factors to support blood cell counts, antibiotics to prevent or treat infection, and pain management as needed. Nutritional support, sometimes through a feeding tube, helps maintain adequate calorie intake, and psychosocial support helps your child and the rest of the family cope with the emotional demands of treatment.

Understanding Prognosis and Follow-Up Care

Outcomes differ significantly by risk group: children with low-risk or intermediate-risk disease generally respond well to treatment, while high-risk disease remains harder to cure despite intensive therapy — a detailed breakdown of survival statistics by risk group is covered separately on this site’s survival-rate page. Long-term follow-up is essential for every child who completes treatment, with regular check-ups, scans, and lab work used to catch any recurrence and spot late effects early, such as hearing loss, heart problems, or a second cancer developing years later. Many pediatric cancer centers offer a dedicated survivorship clinic to coordinate this ongoing care.

Emerging Therapies and Research

Research into the biology of neuroblastoma continues to open new treatment avenues, particularly for children with high-risk or hard-to-treat disease.

Targeted Therapies and Novel Agents

Researchers have identified molecular changes, such as ALK gene mutations, that drive growth in some neuroblastoma tumors. Scientists are studying ALK inhibitors, including lorlatinib, in clinical trials for children and young adults whose neuroblastoma has come back with an ALK alteration, and also in children newly found to have high-risk, ALK-activated disease; these drugs remain investigational and are not yet standard treatment outside a trial. After maintenance therapy, some children with high-risk neuroblastoma also receive eflornithine, a drug that slows cancer cell growth and division, for up to two years to help lower the chance the cancer will return.

The Role of Clinical Trials

Clinical trials give children with high-risk or relapsed neuroblastoma access to treatments not otherwise available, while testing new drugs, drug combinations, and approaches to surgery or radiation. A national clinical trial search tool can help your child’s care team find trials by cancer type, age, and location. Taking part in a trial can benefit your child directly and also builds the evidence that shapes future standard treatment for other children with neuroblastoma.

Frequently Asked Questions

What are the main factors determining neuroblastoma treatment?

The main factors are your child’s age at diagnosis, the stage and location of the tumor, and biological features such as MYCN gene amplification and ALK gene changes. Together, these place the cancer into one of three risk groups — low, intermediate, or high — which then guides how intensive treatment needs to be. A multidisciplinary care team reviews all of this to build a plan suited to your child.

How do doctors manage neuroblastoma treatment side effects?

Care teams use antiemetics for nausea, growth factors to support blood cell counts, antibiotics to prevent infection, and pain management as needed, alongside nutritional and psychological support for your child and family. The goal is to help your child tolerate treatment as safely and comfortably as possible while therapy continues.

What are the latest advancements in neuroblastoma treatment?

Researchers are testing ALK inhibitors such as lorlatinib in clinical trials for neuroblastoma tumors with ALK gene changes, alongside immunotherapy built on anti-GD2 antibodies like dinutuximab for high-risk disease. Clinical trials remain the main way children gain access to these newer treatments before they become standard of care.

Sources

• National Cancer Institute – Neuroblastoma Treatment (PDQ®) – Patient Version
• National Cancer Institute – Neuroblastoma Treatment (PDQ®) – Health Professional Version
• DailyMed (National Library of Medicine) – UNITUXIN (dinutuximab) Injection – Full Prescribing Information
• National Cancer Institute – Late Effects of Treatment for Childhood Cancer (PDQ®) – Health Professional Version